Provided by Tiger Trade Technology Pte. Ltd.

Biogen

210.73
-1.7700-0.83%
Volume:694.67K
Turnover:146.79M
Market Cap:31.11B
PE:37.43
High:213.48
Open:210.50
Low:209.00
Close:212.50
52wk High:225.80
52wk Low:135.39
Shares:147.64M
Float Shares:147.31M
Volume Ratio:0.94
T/O Rate:0.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.63
EPS(LYR):8.79
ROE:4.58%
ROA:5.21%
PB:1.65
PE(LYR):23.97

Loading ...

Biogen Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Yesterday

This Biotech Wins a Big FDA Approval. Why Wall Street is Shrugging.

Dow Jones
·
Sep 05

Correction: Eisai, Biogen Secure China's Nod for Self-Injection Version of Leqembi

MT Newswires Live
·
Sep 04

Stoke Therapeutics, Biogen present long-term data on Zorevunersen

TIPRANKS
·
Sep 04

Stoke Therapeutics, Biogen Report 4-Year Open-Label Data for Dravet Drug Zorevunersen Showing Durable Seizure Reduction

Reuters
·
Sep 04

Stoke Therapeutics and Biogen Present Long-Term Clinical Data That Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16TH European Epilepsy Congress (Eec)

THOMSON REUTERS
·
Sep 04

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

GlobeNewswire
·
Sep 04

Biogen Price Target Raised to $245.00/Share from $225.00 by Piper Sandler

Dow Jones
·
Sep 04

Piper Sander Adjusts Biogen Price Target to $245 From $225, Maintains Overweight Rating

MT Newswires Live
·
Sep 03

Biogen, Eisai announce NMPA of China approves subcutaneous Leqembi

TIPRANKS
·
Sep 03

U.S. Research Roundup-Broadcom, Deere & Co, Snowflake

Reuters
·
Sep 03

Biogen : Piper Sandler Raises Target Price to $245 from $225

THOMSON REUTERS
·
Sep 03

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 03

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16TH European Epilepsy Congress (Eec)

THOMSON REUTERS
·
Sep 01

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

GlobeNewswire
·
Sep 01

Biogen, Eisai announce positive recommendation for Leqembi in Canada

TIPRANKS
·
Sep 01

Eisai: Canada's Drug Agency Issues Final Positive Recommendation for Leqembi Reimbursement in Early Alzheimer's Disease

THOMSON REUTERS
·
Sep 01

Biogen Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 29

Biogen CEO Viehbacher to Speak at Morgan Stanley Global Healthcare Conference

Reuters
·
Aug 28

Biogen CFO Robin Kramer to Join Wells Fargo Healthcare Conference Fireside Chat

Reuters
·
Aug 26